Speed to market remains a key driver for the digitalization of long-standing paper-based processes in drug manufacturing. Bottlenecks such as manual execution and review—all associated with bloated documentation—prevent companies from aligning with the FDA’s vision for advanced manufacturing to achieve continuous improvement. Manufacturers like GlaxoSmithKline (GSK) are embracing Pharma 4.0 and paperless technologies to help bring quality medicines to patients more quickly.
Join Andrew Jenkins, Product Director from GSK, and Craig Resnick, VP of Consulting from ARC, as they discuss:
- Challenges and benefits of switching from paper-based to digital operations
- Solutions that enable pharma manufacturers to digitalize processes such as batch manufacturing execution
- How digitalization processes across the value chain meet evolving business demands
Register today to learn more about the latest technologies that improve usability, reduce risk and ensure compliance.